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Background. In 1996, Brazil became the first developing country to provide free and universal access to HAART. Although a
decrease in overall mortality has been documented, there are no published data on the impact of HAART on causes of death
among HIV-infected individuals in Brazil. We assessed temporal trends of mortality due to cardiovascular diseases (CVD), diabetes
mellitus (DM) and other conditions generally not associated with HIV-infection among persons with and without HIV infection in
Brazil between 1999 and 2004. Methodology/Principal Findings. Odds ratios were used to compare causes of death in
individuals who had HIV/AIDS listed on any field of the death certificate with those who did not. Logistic regression models were
fitted with generalized estimating equations to account for spatial correlation; co-variables were added to the models to control
for potential confounding. Of 5,856,056 deaths reported in Brazil between 1999 and 2004 67,249 (1.15%) had HIV/AIDS listed on
the death certificate and non-HIV-related conditions were listed on 16.3% in 1999, increasing to 24.1% by 2004 (p,0.001). The
adjusted average yearly increases were 8% and 0.8% for CVD (p,0.001), and 12% and 2.8% for DM (p,0.001), for those who had
and did not have HIV/AIDS listed on the death certificate, respectively. Similar results were found for these conditions as
underlying causes of death. Conclusions/Significance. In Brazil between 1999 and 2004 conditions usually considered not to be
related to HIV-infection appeared to become more likely causes of death over time than reported causes of death among
individuals who had HIV/AIDS listed on the death certificate than in those who did not. This observation has important
programmatic implications for developing countries that are scaling-up access to antiretroviral therapy.
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INTRODUCTION
The introduction and widespread use of highly active antiretroviral
therapy (HAART) has had a profound impact on the HIV/AIDS
epidemic, turning a fatal disease into a manageable chronic
condition. As a consequence, marked decreases in AIDS-related
morbidity and mortality have been reported in both low- and high-
income settings [1–5]. However, concerns have been raised about
the consequences of prolonged exposure to antiretroviral drugs, with
some evidence for an association between the use of protease
inhibitors (PIs) and diabetes mellitus (DM) [6] and cardiovascular
diseases (CVD) [7,8]. It has also been recently suggested that HIV
itself may play a contributing role in the pathogenesis of some these
conditions [9]. Several recent studies conducted in developed
countries have documented changes in mortality patterns after the
introduction of HAART. Although causes of death traditionally
associated with HIV/AIDS continue to play a predominant role,
other conditions, including DM, CVD, cancer, liver and renal
diseases have been increasingly reported [10–16].
In 1996, Brazil became the first developing country to provide
free and universal access to HAART. In 2004 147,500 patients
were receiving HAART through the Brazil public health system
[17]. In 2005 WHO estimated that ART coverage in Brazil was in
excess of 80% [18]. Although a decrease in overall mortality has
been documented [3,4], there are no published data on the impact
of HAART on causes of death among HIV-infected individuals in
Brazil.
To our knowledge, there are no population-based studies that
have investigated temporal changes in causes of death among
HIV/AIDS patients in developing countries after the introduction
of HAART. In the present study, we assessed temporal trends of
overall mortality and of selected conditions usually considered not
to be related to HIV-infection as causes of death between 1999
and 2004 in individuals who had and who did not have HIV/
AIDS listed on their death certificate.
RESULTS
A total of 5,856,056 deaths were reported in Brazil between 1999
and 2004. Of these, 67,249 (1.15%) had HIV/AIDS reported in
any field of the death certificate, corresponding to a stable rate of
approximately 6.4 cases/100,000 inhabitants per year during the
study period (p-value for trend = 0.67, Figure 1A, solid circles).
According to official figures from the Brazil Ministry of Health
[19], the death rate associated with HIV/AIDS decreased from
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9.3/100,000 in 1996 to 6.26/100,000 in 1999, and, according to
our data, it has remained relatively stable until 2004 (Figure 1A,
open circles).
In the HIV-group, non-HIV-associated causes of death were
listed in 16.3% of the death certificates in 1999 and steadily
increased to 24.1% in 2004, whereas in the non-HIV group this
ranged from 67.4% to 72.1% in the same period. After adjustment
for age, gender and state of residence, the average yearly increase
of non-HIV-associated causes of death in the HIV group was
7.98% (95%CI = 6.65,9.33; p-value,0.001) and 2.98% for the
non-HIV group (95%CI = 2.22,3.75; p-value,0.001). The slopes
of the increase for the two groups were significantly different (p-
value,0.001). Figure 1B shows temporal trends for the HIV and
for the non-HIV groups, with year as a categorical variable, setting
1999 as the baseline year. In this model, the OR for having a non-
HIV-associated condition listed on the death certificate in 2004
compared to 1999 was 1.6 (95%CI = 1.48,1.72; p-value,0.001)
for the HIV group, and 1.19 (95%CI = 1.14,1.23; p-value,0.001)
for the non-HIV group and (Table 1); the interaction with year as
a categorical variable was also highly significant (p-value,0.001).
CVD increased in the HIV group from 4.3% in 1999 to 6.4% in
2004 (adjusted average increase of 7.79% per year; (95%CI =
5.74,9.66; p-value,0.001). In the non-HIV group, an increase of
0.80% per year was observed (95%CI = 0.28,1.33; p-value =
0.002), from 36.2% in 1999 to 39.3% in 2004. Compared to 1999,
the OR for having CVD listed on the death certificate in 2004 was
1.5 (95%CI = 1.34,1.68; p-value,0.001) for the HIV group and
1.07 (95%CI = 1.04,1.10; p-value,0.001) for the non-HIV groups
(Table 2). Temporal trends for both groups are shown in
Figure 2A; both interactions between year as a continuous or a
categorical variable were significantly different between the two
groups (p-value,0.001).
A similar phenomenon was observed for DM, in which an
adjusted annual increase of 12.3% (95%CI = 8.13,16.56;, p-
value,0.001), from 0.6% in 1999 to 1.4% in 2004 was observed
in the HIV group, in contrast with an adjusted increase of 2.83%
per year in the non-HIV group (95%CI = 1.95,3.72,, p-val-
ue,0.001), from 6.2% in 1999 to 7.7% in 2004 (Figure 2 B,
Table 3). Compared to 1999, the OR for having DM listed on the
death certificate in 2004 was 2.16 (95%CI = 1.65,2.82; p-
value,0.001) for the HIV group and 1.2 (95%CI = 1.13,1.26; p-
value,0.001) for the non-HIV group. The increase in the HIV
group was again steeper than in the non-HIV group, both with
year as a continuous or as a categorical variable (p,0.001).
In the analysis of underlying causes of death among HIV-
infected patients, non-HIV-related conditions, CVD and DM
increased significantly from 1999 to 2004, a result that
corroborates our findings when all causes listed on death
certificates were analyzed (data not shown).
DISCUSSION
The online availability of all death certificates issued in Brazil
provided the opportunity to compare reported causes of death in
1999, the first year in which death certificates contained primary,
secondary, and contributing causes of death according to ICD-10
codes, with later years among individuals who had HIV/AIDS
listed on the death certificate.. To our knowledge, this is the first
report on temporal changes in causes of death among HIV/AIDS
patients at the population level in a developing country in the
HAART era.
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Figure 1. Death Rates and non-HIV-related causes of death. A–Death rates per 100 000 inhabitants of individuals that had HIV/AIDS listed on the
death certificate, 1999–2004 (p-value for trend= 0.67, solid circles) and AIDS mortality as an underlying disease from 1996 to 2004 (open circles). B–
Odds ratios and 95% confidence intervals of non-HIV-related causes of death listed on the death certificate in individuals who had and who did not
have HIV listed on the death certificate. Slopes of trends are significantly different between the two groups (p-value,0.001)
doi:10.1371/journal.pone.0001531.g001
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The present study suggests that, in Brazil, similar to what has
been reported from developed countries, mortality patterns among
HIV/AIDS patients are changing in the HAART era. We found
that, in comparison to 1999, there was a steady and significantly
larger increase in the frequency with which conditions not usually
associated with HIV/AIDS were listed as causes of death
increased for individuals who also had HIV listed on the death
certificate than in individuals who did not, from 16.3% in 1999 to
Table 1. Description and odds ratios of having a non-HIV related condition* in any field of the death certificate stratified by
reported HIV status**
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Variable non-HIV (N=5788807) HIV (N= 67249)
n (%) OR (95% CI) P-value n (%) OR (95% CI) P-value
Outcome Non-HIV-related 4059422 (70.12%) 14746 (21.93%) - -
Year of death 1999 625767 (67.43%) Reference 1774 (16.6%) Reference
2000 649305 (69.39%) 1.07 (1.05–1.1) ,0.001 2317 (21.09%) 1.33 (1.23–1.44) ,0.001
2001 665383 (70.02%) 1.1 (1.07–1.12) 2494 (22.24%) 1.43 (1.31–1.56)
2002 685628 (70.58%) 1.11 (1.08–1.15) 2628 (23.11%) 1.5 (1.38–1.62)
2003 702692 (70.93%) 1.13 (1.09–1.17) 2737 (23.56%) 1.52 (1.4–1.64)
2004 730647 (72.15%) 1.19 (1.14–1.23) 2796 (24.58%) 1.6 (1.48–1.72)
Gender Female 1659581 (68.4%) Reference 4369 (20.98%) Reference
Male 2399841 (71.37%) 1.08 (1–1.17) 0.015 10377 (22.35%) 1.06 (1.01–1.11) 0.03
Age group ,15 97573 (19.46%) Reference 232 (14.14%) Reference
15–29 352801 (83.44%) 20.44 (16.83–24.81) ,0.001 2057 (15.9%) 1.15 (1–1.33) ,0.001
30–39 262805 (76.66%) 12.99 (11.2–15.07) 5387 (20.39%) 1.5 (1.31–1.71)
40–49 390424 (76.88%) 12.79 (11.14–14.69) 4186 (24.59%) 1.89 (1.65–2.16)
50–59 535089 (78.34%) 13.85 (12.1–15.86) 1881 (29.81%) 2.47 (2.14–2.86)
60+ 2400943 (72.69%) 10.39 (9.07–11.9) 974 (35.63%) 3.25 (2.81–3.76)
Unknown 19787 (71.11%) 9.29 (7.93–10.88) 29 (15.85%) 1.17 (0.76–1.8)
*non-HIV-related neoplasms (C00-C80, except C46–Kaposi’s sarcoma), DM (E10-E14), CVD (I00-I99), except cardiac arrest (I46), digestive diseases (K00-K93), genital-
urinary diseases, (N00-N99) and external causes (S00-Y98)
**Adjusted for state of residency
doi:10.1371/journal.pone.0001531.t001..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
Table 2. Description and odds ratios of having CVD* in any field of the death certificate stratified by reported HIV status**
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Variable non-HIV (N=5788807) HIV (N= 67249)
n (%) OR (95% CI) P-value n (%) OR (95% CI) P-value
Outcome CVD 2196228 (37.94%) 3746 (5.57%) - -
Year of death 1999 341452 (36.8%) Reference 491 (4.59%) Reference
2000 360784 (38.56%) 1.07 (1.05–1.09) ,0.001 579 (5.27%) 1.14 (1–1.3) ,0.001
2001 368185 (38.75%) 1.06 (1.04–1.09) 647 (5.77%) 1.25 (1.1–1.43)
2002 375371 (38.64%) 1.05 (1.02–1.07) 721 (6.34%) 1.38 (1.22–1.57)
2003 386117 (38.97%) 1.05 (1.02–1.07) 750 (6.46%) 1.39 (1.23–1.57)
2004 404072 (39.9%) 1.07 (1.04–1.1) 800 (7.03%) 1.5 (1.34–1.68)
Gender Female 1067296 (43.99%) Reference 1241 (5.96%) Reference
Male 1168685 (34.76%) 0.79 (0.75–0.82) ,0.01 2747 (5.92%) 0.98 (0.91–1.05) 0.96
Age group ,15 23306 (4.65%) Reference 101 (6.15%) Reference
15–29 33154 (7.84%) 1.75 (1.43–2.14) ,0.001 480 (3.71%) 0.59 (0.47–0.75) ,0.001
30–39 62250 (18.16%) 4.46 (4.01–4.97) 1331 (5.04%) 0.79 (0.62–0.99)
40–49 162441 (31.99%) 9.22 (8.54–9.95) 1103 (6.48%) 1.01 (0.8–1.28)
50–59 289154 (42.33%) 14.33 (13.34–15.39) 590 (9.35%) 1.51 (1.18–1.93)
60+ 1661862 (50.31%) 19.56 (18.18–21.05) 379 (13.86%) 2.37 (1.85–3.04)
Unknown 3814 (13.71%) 3.53 (2.48–5.02) 4 (2.19%) 0.35 (0.11–1.16)
*CVD: ICD10 I00-I99, except cardiac arrest (I46)
**Adjusted for state of residency
doi:10.1371/journal.pone.0001531.t002..
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24.1% in 2004, representing 14,746 deaths in the period. In
particular, listing of CVD or DM as causes of death represented
3,746 and 744 deaths, respectively, both appearing to become
more likely causes of death over time in individuals whose death
certificate also included HIV/AIDS than in those who did not.
Additionally, during the same period there were statistically
Table 3. Description and odds ratios of having DM* in any field of the death certificate stratified by reported HIV status**
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Variable non-HIV (N= 5788807) HIV (N= 67249)
n (%) OR (95% CI) P-value n (%) OR (95% CI) P-value
Outcome DM 411862 (7.11%) 744 (1.11%) - -
Year of death 1999 57312 (6.18%) Reference 63 (0.59%) Reference
2000 65525 (7%) 1.12 (1.08–1.16) ,0.001 109 (0.99%) 1.62 (1.21–2.15) ,0.001
2001 66886 (7.04%) 1.12 (1.08–1.16) 130 (1.16%) 1.87 (1.39–2.52)
2002 71025 (7.31%) 1.15 (1.1–1.2) 117 (1.03%) 1.63 (1.23–2.17)
2003 72933 (7.36%) 1.15 (1.1–1.2) 161 (1.39%) 2.13 (1.63–2.77)
2004 78181 (7.72%) 1.2 (1.13–1.26) 164 (1.44%) 2.16 (1.65–2.82)
Gender Female 235268 (9.7%) Reference 240 (1.15%) Reference
Male 176594 (5.25%) 0.59 (0.55–0.64) ,0.01 504 (1.09%) 0.9 (0.77–1.04) 0.19
Age group ,15 617 (0.12%) Reference 0 (0%) Reference
15–29 3309 (0.78%) Reference 42 (0.32%) Reference
30–39 6811 (1.99%) 4.86 (3.96–5.95) ,0.001 171 (0.65%) 2.15 (1.53–3.03) ,0.001
40–49 22329 (4.4%) 10.59 (8.74–12.82) 244 (1.43%) 4.68 (3.37–6.49)
50–59 57967 (8.49%) 20.94 (17.32–25.32) 163 (2.58%) 8.58 (6.15–11.97)
60+ 320444 (9.7%) 23.07 (19.04–27.96) 122 (4.46%) 15.24 (10.96–21.19)
Unknown 385 (1.38%) 3.89 (2.06–7.33) 2 (1.09%) 4 (1–16.09)
*DM: ICD10 E10-E14, except cardiac arrest (I46)
**Adjusted for state of residency
doi:10.1371/journal.pone.0001531.t003..
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Figure 2. CVD and DM in HIV-infected/AIDS patients. Odds ratios and 95% confidence intervals comparing the chance of having the disease listed
on the death certificate over time, compared with 1999. A–CVD; B–DM. Slopes for trends are significantly different between groups for CVD (p-
value,0.001) and DM (p-value,0.001).
doi:10.1371/journal.pone.0001531.g002
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significant increases in these conditions as underlying causes of
death among individuals who had HIV/AIDS mentioned on their
death certificates.
We speculate that theses changes are not explained by aging of the
population alone, given that the mean age of death in the non-HIV
group increased marginally more than the mean age of death in the
HIV group (data not shown). Thus, certain potentially preventable
and/or treatable conditions, such as CVD and DM, may have
played significant roles in these changes, given that the proportion of
death certificates in which these conditions are listed increased
significantly faster in individuals for whom HIV was listed on the
death certificate than in those for whom it was not listed.
Our results are in agreement with reports from developed
countries where the sharp decrease in mortality following the
introduction of HAART was accompanied by significant changes
in mortality patterns among HIV-infected individuals. In these
countries, after a steep decrease in mortality rates following the
introduction of HAART, mortality rates have been reasonably
stable since the late 1990’s. For example, in the United States,
mortality rates declined abruptly in 1994/1995, but remained
stable from 1998 onwards, at approximately 7 deaths/100,000
population [20,21]. In countries where HIV prevalence is well
defined and thus could be used as the denominator, a steady
increase in the proportion of deaths attributed to conditions that
generally are not attributed to HIV infection, such as CVD and
DM [5,10–14], has been reported. We were not able to perform
similar analyses, given the absence of reliable estimates of HIV
prevalence in most regions of Brazil.
Our results are also in agreement with what has been reported
in population-based studies conducted in developed countries. For
example, combining information on HIV/AIDS surveillance in
New York City with vital statistics data, Sackoff et al. [11] showed
an increase in the proportion of non-HIV/AIDS-related causes of
death from 19.8% to 26.3% between 1999 and 2004, with CVD
ranking second overall and DM reaching 4.4% of all non-HIV-
related causes of death in women. In another population-based
study in the U.S., Selik et al., using a similar approach to ours but
limiting the analysis only to those who had HIV/AIDS listed on
the death certificate, showed that CVD increased from 4% to
7.7% from 1987 to 1999, with a steeper increase between 1996
and 1999 [14]. Similar trends have also been documented in
cohort studies. In the CASCADE Collaboration, CVD and DM as
a group increased from 1.3% in the pre-HAART era to 4.3% in
post-HAART era [12]. In the HIV Outpatient Study, Palella et al.
showed that non-HIV/AIDS-related causes of death increased
from 13.1% to 42.5% between 1996 and 2004 in 12 clinics in the
United States, with CVD being leading cause of death in this
group in 2004 [13]. Crum et al., studying an HIV cohort of U.S.
military beneficiaries, also showed increases in cardiac disease
(from 8% to 22%) and DM (from 0% to 3%) being listed on death
certificates in the pre- and post-HAART era, respectively [10]. In
a simulation study, Braithwaite et al predicted that HIV-infected
patients will be increasingly dying of co-morbidities not related to
HIV infection. For example, they predicted that a 30 years old
patient with a high CD4 count and low viral load would have a
45% chance of dying from non-HIV related causes, and that up to
35% of these would be CVD [15]. Given the absence of reliable
estimates of HIV prevalence in most regions of Brazil, we were not
able to provide estimates of actual trends among HIV-infected
individuals. Nonetheless, we believe that our findings are likely to
reflect a changing mortality pattern among HIV/AIDS patients in
Brazil that could be associated with widespread availability of
HAART [22], a pattern similar to that in developed countries. It
should be noted that it is estimated that over 80% of HIV infected
patients who, according to international guidelines, were in need
of treatment in Brazil were on antiretroviral therapy during the
study period[18].
A major strength of our study is that we analyzed all available data
from all death certificates issued in a large developing country over a
six year period, which allowed us to investigate temporal trends in
causes of death by comparing individuals who had HIV/AIDS listed
in their death certificates to those who did not. Furthermore, the use
of any mention of conditions on the death certificate as opposed to
only the underlying cause of death allowed us to overcome one of the
limitations of the current ICD system, which does not cover some
diseases associated with HIV [16], as well as to capture the
contributing effect of other conditions. Since HIV-infected individ-
uals now live longer [10,13] and thus have longer periods of time at
risk for chronic conditions associated with aging, an increase in the
frequency of CVD and DM is to be expected. There are also data
that indicate an association between certain antiretroviral drugs as
well as time on therapy and risk for CVD [7,23]. Additionally, recent
data suggest that HIV replication may be associated with increased
levels of pro-inflammatory markers which, in turn, are involved in
the pathogenesis of CVD [9].
Our study has several limitations. Most importantly, we only
analyzed data from death certificates, which may lack sensitivity
and specificity for medical conditions [24–26]. Nonetheless, by
using an approach akin to MOR [27], a strategy that is commonly
utilized in studies that investigate occupational hazards, we were
able to estimate relative risks by comparing individuals who had
HIV/AIDS cited in their death certificates to those who did not.
The main difference from the classical use of MOR was that the
focus of our analysis was not to compare risks between groups, but
to compare temporal trends among them. This approach was
chosen due to the lack of reliable estimates of the prevalence of
HIV infection in Brazil, particularly age and gender distribution.
Additionally, as is the case for all population-based studies, we
cannot exclude the influence of unknown confounders that may
have contributed to increased reports of non-HIV associated
causes of death or to changes over time in the frequency in which
HIV/AIDS is listed on death certificates. The latter, if present,
probably did not play a significant role, given the stable rate of
HIV/AIDS being listed on death certificates, which in turn is in
agreement with reports that indicate that HIV-related mortality
has remained stable since 1999 [3,4]. Information on the
proportion of those who had HIV/AIDS listed on their death
certificate and who were or had been on antiretroviral therapy is
not available, as well as other important confounders such as
smoking and other risk factors for CVD, and thus could not be
assessed in our analyses. However, since HAART is freely and
universally available for all those who qualify for treatment
according to treatment guidelines that are virtually identical to
those used in developed countries [28,29], it is likely that the vast
majority of those who had HIV/AIDS listed on the death
certificate were or had been on HAART.
In conclusion, this is the first study to examine changes in
mortality patterns among HIV-infected individuals in Brazil after
the introduction of HAART. Of particular importance is the
finding that conditions that potentially may be prevented and/or
treated, such as CVD and DM, have appeared to become more
likely causes of death over time among HIV-infected individuals
than in the general population. The immediate implication of this
finding is that the clinical management of persons living with
HIV/AIDS should include prevention, diagnosis, and treatment of
chronic conditions, such as CVD and DM. At the program level,
the Brazilian network of treatment facilities will need to increase its
capacity to diagnose and manage co-morbidities that can influence
Mortality HIV HAART Brazil
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outcome. This, in turn, reinforces the need to integrate HIV/
AIDS programs with other public health programs, in order to
establish a healthcare infrastructure that is capable to take the
necessary measures to prevent, diagnose, and treat these
conditions [30]. Finally, for other developing countries that are
just starting to scale-up their programs, lessons learned from the
Brazilian experience might help to prepare in advance to changes
in morbidity and mortality patterns that will likely occur once
HAART becomes widely available.
MATERIALS AND METHODS
In Brazil the death certificate is a standardized form that is filled
out by a physician. Until 1998, death certificates only included the
underlying cause of death. Since 1999, death certificates, besides
containing demographic information, include primary, secondary,
and contributing causes of death according to the International
Classification of Diseases 10th revision (ICD-10) codes [24]. All
death certificates issued in Brazil are entered in datasets without
personal identifiers and are available online at http://tabnet.
datasus.gov.br/tabdata/sim/dados/cid10_indice.htm. This na-
tional database is known as the Brazilian Mortality Information
System (Sistema de Informac¸o˜es sobre Mortalidade [SIM]).
In this study, we investigated trends for all causes of death
mentioned on death certificates in Brazil between 1999 and 2004.
During the study period Brazil had a population of approximately
173 million people [31]. We compared temporal trends in causes
of death among individuals who had HIV/AIDS listed in any field
of the death certificate (ICD-10 codes B20-B24, Z21), referred to
as the HIV group, with those who did not have HIV/AIDS
reported on the death certificate (the non-HIV group) using an
approach akin to the mortality odds-ratio (MOR) focusing on
temporal trends, not on the risk of dying with the studied causes,
which would be the classical use of MOR [27].
We conducted three separate analyses, in which the outcomes
were defined as the presence or absence in any field of the death
certificate of: [I] non-HIV-associated causes, defined as non-HIV-
related neoplasms (C00-C80, except C46–Kaposi’s sarcoma), DM
(E10-E14), CVD (I00-I99), except cardiac arrest (I46), digestive
diseases (K00-K93), genital-urinary diseases, (N00-N99) and
external causes (S00-Y98); [II] CVD (I00-I99), except cardiac
arrest (I46); and [III] DM (E10-E14). Additionally, we also
examined these outcomes as the underlying cause of death, as
defined by the World Health Organization (WHO), in individuals
who had HIV/AIDS mentioned on their death certificates [32].
The underlying cause of death, which consists of only one cause
per death certificate, is coded by local health departments based
on standard rules [33], and is the official figure reported by the
Brazil Ministry of Health to WHO for mortality statistics.
Logistic regression models were fitted and co-variables were
added to the models to control for possible confounding, including
age group (,15; 15–29; 30–39; 40–49; 50–59; .= 60 years);
gender; year of death; and state of residence. Age groups were
used to avoid low numbers in some regions of the curves.
Generalized estimating equations (GEE) were used to fit the
logistic models and to account for spatial correlation structures in
the data (i.e. using state of residence as clusters), which were
assumed to be interchangeable for this analysis.
Year of death was treated either as a continuous (linear) or
categorical variable in the models. In the former case, linear trends
are reported as percentages per year, while in the latter, odds
ratios are used to compare yearly changes to the baseline year of
1999. Differences in slopes in temporal trends were tested by an
interaction term between HIV status and year. Reference groups
were ,15 years for age, female for gender, and Sa˜o Paulo State
for state of residence.
All analyses were performed in R for Windows v. 2.4.1 [34],
using the package ‘geepack’ for GEE estimation [35].
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